"Related information," the thirteenth item of a comprehensive product information summary, is unglamorous, yet it mirrors the character of the Creation Guide well. Unlike efficacy or clinical data, it does not draw the reader in. It records, in dates and numbers, when a product passed through which public procedures and where it now stands: the approval number, the approval date, listing on the drug price standard, the start of marketing, any conditions attached to approval, matters concerning insurance reimbursement, and the milestones of re-examination and reevaluation. None of these are things a company narrates freely. They move according to regulatory judgment and official notice. Whether this section can be written accurately is a touchstone for whether the entire material is "built to be verifiable."
The foreword positions the product information summary as a "supplement" to the electronic package insert. The approved content is the original; the material sits beneath it. Each entry of related information is a coordinate pointing to which procedure gave rise to that original and how far it is publicly substantiated — an anchor that ties the material to the facts of approval.
01Why bother listing "dates and numbers"
Much of related information looks like a string of figures. But the intent of placing the date of preparation or revision as the closing item, with this section just before it, is clear: to let the reader cross-check facts afterward — that is, to guarantee verifiability through structure. An approval number can be matched against the official notice. An approval date lets one trace which indications were recognized at that point. The dates of price listing and marketing start say whether the product is actually usable in clinical practice.
The integrity of this section shows not only in the correctness of the figures written but also in how unwritten items are handled. The Creation Guide asks that, where no applicable information exists, the item heading itself be omitted. Leaving a blank with only "none" to hint at existence, or making something undetermined look settled, may not breach the duty not to lie, but it does collide with the duty not to mislead. A section that looks free of the temptation to "present things favorably" in fact tests integrity on both sides — omission and commission.
02Writing the approval number and date correctly
The approval number and date are the core of the fact that the product obtained approval under the Pharmaceuticals and Medical Devices Act. For products where indications were added later, the dates of those additional approvals are recorded up to the most recent one. Listing only the first approval date and saying nothing of later additions misrepresents where the product now stands.
For drugs that do not require approval, the marketing business license number is recorded in place of the approval number. The international birth date is supplementary information that may be appended when needed.
How far to follow additional approvals
For products whose indications were added more than once, the phrase "up to the most recent" carries weight. Keeping only the old approval date and omitting the latest indication addition may lead the reader to mistake that indication as still off-label. Conversely, lining up unapproved indications under application as if approved is not permitted either. The approval date must be accurate as a mirror reflecting the approved scope at that moment.
03Handling the drug price listing date
The date of listing on the drug price standard bears directly on whether the product can be used under insured care. If not yet listed, that fact is stated. At the new-launch stage the listing date may not be settled; in that case the practice of showing only "listed on the drug price standard" and entering the confirmed date at reprinting is permitted.
When a unit price is given, the date of listing or revision is shown alongside it. Because drug prices move with revisions, a unit price without a date leaves the reader unable to tell as of when the price holds, and thus misleads.
In a "product list" lining up related products, a drug price list may carry the unit price only — not the daily drug cost or the patient's out-of-pocket amount. The same discipline applies in the related information section. Attaching a date to the unit price hands the reader the premise that prices shift over time.
04Marketing start date and conditions of approval
The marketing start date may be left blank at new launch or when the timing is undetermined, with the confirmed date entered at reprinting. Where it is genuinely unknown, "unknown" is written. Here too the principle holds: do not present the undetermined as settled.
Conditions of approval are written according to the electronic package insert. If there is no information on a condition, that item heading is not written at all. A summary is acceptable as long as the content is unchanged, but the summary must not distort the intent of the condition.
What "omit the item entirely" means
When applicable information is absent, the Guide steers writers away from leaving the heading with an empty body. An empty heading raises the reader's expectation that "something should be here," and so produces a false impression. If there is no information, do not place the item at all. This is the foreword's concern — that a single way of presenting can breed misunderstanding — made concrete in the quietest of sections.
05Matters concerning insurance reimbursement
Under matters concerning insurance reimbursement, one records that the product is outside reimbursement, or only partly covered, or information on drugs subject to dosing-period limits. This is practical information on a different axis from efficacy or safety — it shapes how the product can actually be used. Failing to convey the scope of reimbursement accurately risks prescribing decisions in the field diverging from fact. For products to which this does not apply, the item is not set up.
06Re-examination and reevaluation as a time axis
A drug's evaluation does not end at approval. Re-examination is conducted in light of post-marketing use, and reevaluation is applied as needed. Related information records the milestones of this time axis too.
When a re-examination period expires, its expiry date is recorded; when re-examination results are published, that publication date is recorded. For products whose re-examination period differs by indication, the expiry date and the number of years of the period are shown for each indication. Results are recorded as the most recent ones. The publication date of reevaluation results is likewise recorded as the most recent, but reevaluation concerning quality need not be recorded.
| Item | What to record | When undetermined / not applicable |
|---|---|---|
| Approval number / date | Indication additions up to the latest approval date. License number for drugs not requiring approval | International birth date optional |
| Drug price listing date | Unit price shown with listing/revision date | State if not listed. At launch "listed on standard" allowed, date at reprinting |
| Marketing start date | Confirmed date | Blank allowed at launch/undetermined, entered at reprinting. "Unknown" if unknown |
| Conditions of approval | Per electronic package insert. Summary allowed if unchanged | If no information, omit the item entirely |
| Insurance reimbursement | Outside coverage / partial / dosing-period limits | If not applicable, do not set up the item |
| Re-examination | Expiry date and years per indication; latest publication date for results | — |
| Reevaluation | Latest result publication date | Quality-related reevaluation need not be recorded |
Why quality reevaluation is excluded
That reevaluation concerning quality is left out of the recording scope can be read as following from this section's purpose: to let healthcare professionals trace the current state of efficacy and safety evaluation. Quality reevaluation is a procedure on the manufacturing-control side, different in character from the evaluation axis that bears directly on prescribing decisions. Even the line between what is recorded and what is not reflects the section's intent.
Related information carries no flashy prohibitions. Yet the unglamorous task of accurately stacking up everything from the approval number to the dates of re-examination and reevaluation is exactly what keeps a material in a state where it can later be verified and, if needed, recalled or revised. Together with the main references, the marketing-authorization holder, and the date of preparation or revision that follow, this section hands the reader the answer to "when, by whom, and on which approval this was made."
Do not present the undetermined as settled. Omit items that do not apply, heading and all. Attach a date to the unit price. Each is a small convention, but their accumulation implements, in the quietest place, the foreword's spirit of conveying accurately without misleading.